The long-term administration of BLZ945 (0.1 mg/mL), a control CSF1R inhibitor, exhibited tumor growth inhibition comparably to FF-10101 (0.1 mg/mL) (Figure 7B). The gene discussed is CSF1R; the disease is neoplasm.